Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia
Abstract
Objective To examine changes in cognitive function and clinical features after a switch from atypical antipsychotics to aripiprazole in patients with schizophrenia. Method Sixty-one patients with schizophrenia treated with atypical antipsychotics participated in this open-label, 26-week study. Antipsychotics were switched to aripiprazole, and neurocognitive functions were measured at 12 and 26 weeks using the computerized battery. The secondary outcome measures were the Positive and Negative Syndrome Scale, the Social and Occupational Functioning Assessment Scale, the Calgary Depression Scale for Schizophrenia, the Subjective Well-being Under Neuroleptics Scale, and the Drug Attitude Inventory (DAI). The safety measures included metabolic parameters, the Simpson-Angus Rating Scale, the Barnes Akathisia Scale, and the Abnormal Involuntary Movement Scale. Results Significant improvements in cognitive function were observed in the Verbal Learning Test, the Wisconsin Card Sorting Test, and the Trail Making Test part A after a switch to aripiprazole. Scores on the Positive and Negative Syndrome Scale, the Social and Occupational Functioning Assessment Scale, the DAI, the Simpson-Angus Rating Scale, and the Abnormal Involuntary Movement Scale were significantly improved. The metabolic parameters, including serum cholesterol levels, were also improved. The changes in cognitive measures were not correlated with the changes in positive symptoms or movements scales. The improvement of…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The generalizability of the population could be affected by the short duration of exposure in the open label, stabilization phase prior to randomization.
“Finally, the generalizability of the population could be affected by the short duration of exposure in the open label, stabilization phase prior to randomization, as duration of prior exposure might be important, as pointed out by Kim et al. (30).”
From Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis (2021) · cites this paper as Kim et al. [30]
Cited by
Sorted by citations
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112 · see citing works
Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Speyer, H., Westergaard, C., Albert, N., Karlsen, M., Stürup, A. E., Nordentoft, M., & Krogh, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.577919 · Cited by 44 · see citing works
Sugawara Kikuchi, Y., & Shimizu, T. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189050 · Cited by 14 · see citing works
- Authors
- Kim, S.-W., Shin, I.-S., Kim, J.-M., Lee, J.-H., Lee, Y.-H., Yang, S.-J., & Yoon, J.-S.
- Affiliations
- Chonnam National University (KR)
- Corresponding author
- Kim, Sung-Wan
- Shin, Il-Seon
- Kim, Jae-Min
- Yoon, Jin-Sang
- Venue
- Clinical Neuropharmacology
- Published
- 2009-09
- Volume
- 32
- Issue
- 5
- Pages
- 243-249
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W1963544666
- Cited by
- 47
- References
- 0
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 7 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Otsuka Pharmaceutical
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- aripiprazole, atypical antipsychotics, antipsychotic switching, schizophrenia, cognitive function, neurocognitive impairment, metabolic abnormalities, serum cholesterol, akathisia, tardive dyskinesia, treatment duration, attitudes toward medication, social functioning, positive and negative symptoms
- MeSH terms
- Aripiprazole, Adolescent, Adult, Drug Administration Schedule, Humans, Middle Aged, Neuropsychological Tests, Piperazines, Prospective Studies, Reaction Time, Schizophrenia, Antipsychotic Agents, Quinolones, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
